SCHEMBL25310936

SCHEMBL25310936

O=C(c1cccc(-c2cn3ccccc3n2)c1)N1CC2CN(C(=O)c3cccc(-c4cn5ccccc5n4)c3)CC2C1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.58
SMN1; SMN2 Q16637 6/20 0.58
RAB9A P51151 5/20 0.58
LMNA P02545 4/20 0.58
POLB P06746 3/20 0.58
GFER P55789 2/20 0.58
ALDH1A1 P00352 11/20 0.56
HPGD P15428 4/20 0.56
GAA P10253 3/20 0.55
HSD17B10 Q99714 3/20 0.55
NPSR1 Q6W5P4 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
KMT2A Q03164 3/20 0.53
MAPT P10636 3/20 0.53
CASP3 P42574 1/20 0.52
SENP8 Q96LD8 1/20 0.52
SENP7 Q9BQF6 1/20 0.52
SENP6 Q9GZR1 1/20 0.52
TP53 P04637 2/20 0.52
NPC1 O15118 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25882701 0.95 KDM4E (0.56) KDM4ESMN1; SMN2RAB9ALMNAPOLB
SCHEMBL25310339 0.92 KDM4E (0.53) KDM4ESMN1; SMN2RAB9ALMNAPOLB
SCHEMBL25880948 0.89 KDM4E (0.49) KDM4ESMN1; SMN2RAB9ALMNAPOLB
SCHEMBL25311377 0.89 KDM4E (0.62) KDM4ESMN1; SMN2RAB9ALMNAPOLB
SCHEMBL19322175 0.87 KDM4E (0.60) KDM4ESMN1; SMN2RAB9ALMNAPOLB
SCHEMBL25878144 0.86 KDM4E (0.57) KDM4ESMN1; SMN2RAB9ALMNAPOLB
SCHEMBL25877650 0.86 KDM4E (0.55) KDM4ESMN1; SMN2RAB9ALMNAPOLB
SCHEMBL25881998 0.85 KDM4E (0.46) KDM4ESMN1; SMN2RAB9ALMNAPOLB
SCHEMBL25311112 0.84 KDM4E (0.55) KDM4ESMN1; SMN2RAB9ALMNAPOLB
SCHEMBL25312109 0.84 KDM4E (0.56) KDM4ESMN1; SMN2RAB9ALMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240101552-A1 CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2024-03-28 US disclosed
EP-4215526-A1 CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF Shanghai Pharmaceuticals Holding Co., Ltd. (CN) 2023-07-26 EP disclosed
EP-4215526-A1 CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF Shanghai Pharmaceuticals Holding Co., Ltd. (CN) 2023-07-26 EP disclosed
CN-114195780-A Carbonyl heterocyclic compound and application thereof 上海医药集团股份有限公司 2022-03-18 CN disclosed
CN-114195806-A Carbonyl heterocyclic compound and application thereof 上海医药集团股份有限公司 2022-03-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240101552-A1 CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF LANCL2, CBS, LCP2 KDM4E 2757/4885SMN1; SMN2 3536/4885RAB9A 2591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.